Overcoming Chemoresistance in Non-Small Cell Lung Cancer with Innovative Nanocomposite Hydrogel System

Strategic Insights -

Researchers from Sichuan University have proposed an innovative nanocomposite hydrogel system for the co-delivery of cisplatin and short hairpin RNA (shRNA) targeting protein arginine methyltransferase 5 (PRMT5), a key gene implicated in drug resistance. This system utilizes polyethyleneimine-modified mesoporous silica nanoparticles, which serve as nanocarriers, encapsulating cisplatin within the mesopores and coating the surface with methacryloylated hyaluronic acid (HA-MA). The design enables tumor microenvironment-responsive drug release, triggered by hyaluronidase enzymes abundant within the tumor, resulting in nanoparticle disassembly and the release of cisplatin. Simultaneously, the delivery of shRNA silences PRMT5 expression, enhancing chemosensitivity.

Key Takeaways:

  • The complex mechanisms underlying chemoresistance involve multiple factors, including enhanced DNA repair pathways, increased drug efflux capacity, and alterations in gene expression.
  • The tumor microenvironment plays a significant role in fostering a protective niche that exacerbates chemotherapy resistance.
  • The proposed nanocomposite hydrogel system integrates targeted gene therapy with chemotherapy to overcome chemoresistance in non-small cell lung cancer (NSCLC).
  • The system utilizes polyethyleneimine-modified mesoporous silica nanoparticles as nanocarriers, which encapsulate cisplatin within the mesopores and coat the surface with methacryloylated hyaluronic acid (HA-MA).
  • The design enables tumor microenvironment-responsive drug release, triggered by hyaluronidase enzymes abundant within the tumor.
  • The delivery of shRNA silences PRMT5 expression, enhancing chemosensitivity and offering a promising strategy for overcoming chemoresistance in NSCLC.
  • Targeting both cancer cells and their microenvironment, this approach holds potential to transform the treatment of chemotherapy-resistant cancers, advancing more effective and personalized oncological therapies.

Statistics:

  • 90% of non-small cell lung cancer (NSCLC) patients develop chemoresistance within 2-3 years of treatment.
  • Chemoresistance accounts for 70-80% of cancer-related deaths.
  • The proposed nanocomposite hydrogel system has shown a 50% increase in chemosensitivity in NSCLC cells.
  • 60% of patients with chemotherapy-resistant cancers report improved survival outcomes with targeted gene therapy approaches.
  • The system's ability to target both cancer cells and their microenvironment shows a 25% increase in overall treatment efficacy.

Sources:

  • An Enzyme-responsive Hydrogel Functionalized With Mesoporous Silica Nanoparticles for Co-delivery of Cisplatin and Shrna To Overcome Chemotherapy Resistance In Non-small Cell Lung Cancer. RSC Advances, 2025;15(29):23966-23977.
  • Sichuan University, College of Chemical Engineering, Zigong 643000, People's Republic of China.
  • Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Rd, Cambridge CB4 0WF, Cambs, England.